Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet

Day One Biopharmaceuticals, Inc. (DAWN) closed the last trading session at $15.01, gaining 1.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $36.13 indicates a 140.7% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $6.33. While the lowest estimate of $24 indicates a 59.9% increase from the current price level, the most opt ...